NCT06099535View on ClinicalTrials.gov

A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

December 29, 2022

Study Completion Date

April 11, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

LNK01001 Dose A

Capsules taken orally

DRUG

LNK01001 Dose B

Capsules taken orally

DRUG

placebo

Capsules taken orally

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Lynk Pharmaceuticals Co., Ltd

INDUSTRY

NCT06099535 - A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter